Teva Pharma Industries Ltd ADR
$ 35.01
-1.13%
31 Jul - close price
- Market Cap 40,797,016,000 USD
- Current Price $ 35.01
- High / Low $ 35.66 / 34.56
- Stock P/E 58.35
- Book Value 6.65
- EPS 0.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 37.35
- 52 Week Low 15.46
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Analyst Target Price
$41.20
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-01-28 | 2025-11-05 | 2025-07-30 | 2025-05-07 | 2025-01-29 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-01-31 | 2023-11-08 |
| Reported EPS | 0.64 | 0.53 | 0.96 | 0.75 | 0.66 | 0.52 | 0.71 | 0.69 | 0.61 | 0.48 | 1 | 0.6 |
| Estimated EPS | 0.05 | 0.46 | 0.64 | 0.66 | 0.62 | 0.46 | 0.7 | 0.66 | 0.55 | 0.51 | 0.76 | 0.61 |
| Surprise | 0.59 | 0.07 | 0.32 | 0.09 | 0.04 | 0.06 | 0.01 | 0.03 | 0.06 | -0.03 | 0.24 | -0.01 |
| Surprise Percentage | 1180% | 15.2174% | 50% | 13.6364% | 6.4516% | 13.0435% | 1.4286% | 4.5455% | 10.9091% | -5.8824% | 31.5789% | -1.6393% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.085 | $0.07225 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TEVA
2026-08-01 10:39:22
Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries Ltd. by 1.5% in Q1, holding 4.82 million shares valued at $145.08 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating with an average price target of $42.00. Despite recent insider share sales totaling approximately $10.5 million, the company has seen positive sentiment from analyst upgrades and strong sales in key branded products like UZEDY.
2026-08-01 08:39:22
Axiom Investment Management LLC has acquired a new position of $965,000 in Teva Pharmaceutical Industries Ltd. during the first quarter, purchasing 32,032 shares. Institutional investors collectively own about 54.05% of the company, and analysts have a "Moderate Buy" consensus with an average target price of $42.00, despite recent insider share sales totaling $10.5 million. Teva recently reported $4.14 billion in revenue but incurred a $576 million net loss in its latest quarter, though it raised its 2026 revenue guidance due to strong performance in branded drugs like UZEDY.
2026-08-01 06:39:22
Teva Pharmaceutical Industries Limited reported total revenue of 53.44 billion ILS last year. The Generics, Innovative Medicines and Biopharmaceuticals segment was the top performer, contributing 59.53 billion ILS, although this was a decrease from the previous year. The United States was the largest regional contributor, accounting for 31.68 billion ILS in revenue.
2026-07-31 10:09:58
RBF Capital LLC has reduced its stake in Teva Pharmaceutical Industries Ltd. by 60%, selling 30,000 shares and retaining 20,000 shares worth $602,000. This divestment occurred despite Teva reporting strong Q2 revenue of $4.14 billion, surpassing estimates, and raising its 2026 revenue outlook due to growth in innovative medicines and UZEDY sales. However, the company's Q2 EPS of $0.02 missed expectations, leading to a $576 million net loss.
2026-07-31 08:09:58
Dimensional Fund Advisors LP increased its stake in Teva Pharmaceutical Industries Ltd. by 2.6%, acquiring an additional 73,410 shares and bringing its total holdings to 2.86 million shares valued at approximately $86.2 million. Institutional investors collectively own 54.05% of Teva, whose recent Q2 revenue of $4.14 billion exceeded estimates, driven by strong growth in innovative medicines, though EPS missed consensus and the company reported a net loss. Analysts maintain a "Moderate Buy" consensus with an average price target of $42.00, despite some recent insider selling.
2026-07-31 05:09:58
Teva Pharmaceutical Industries (TEVA) saw its stock inch up despite reporting a significant net loss of US$576 million in Q2 2026, primarily due to acquisition-related R&D charges. While overall revenue remained steady, the company's branded neurology assets, including AUSTEDO, AJOVY, and UZEDY, showed strong growth, leading to raised full-year guidance for these products. However, the loss, combined with a decline in generics revenue and reliance on a few key brands, raises concerns about debt coverage and the quality of future earnings.
